Meeder Asset Management Inc Lipocine Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 17, 2019	SELL	$1.79 - $3.33 $6,100 - $11,348	-3,408 Closed	0 $0
Q1 2019 Apr 16, 2019	SELL	$1.46 - $2.33 $4,374 - $6,980	-2,996 Reduced 46.78%	3,408 $8,000
Q4 2018 Jan 17, 2019	BUY	$1.07 - $1.63 $455 - $694	426 Added 7.13%	6,404 $8,000
Q3 2018 Nov 02, 2018	BUY	$1.31 - $1.63 $4,710 - $5,861	3,596 Added 150.97%	5,978 $0
Q2 2018 Jul 24, 2018	SELL	$1.06 - $1.78 $65 - $110	-62 Reduced 2.54%	2,382 $0
Q1 2018 May 03, 2018	SELL	$1.18 - $3.46 $89 - $262	-76 Reduced 3.02%	2,444 $4,000
Q4 2017 Feb 02, 2018	BUY	$3.36 - $4.35 $2,899 - $3,754	863 Added 52.08%	2,520 $9,000
Q3 2017 Oct 20, 2017	BUY	$3.67 - $4.19 $6,081 - $6,942	1,657	1,657 $7,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $459M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.